CN106265891A - 一种维生素e胶囊及其制备方法 - Google Patents
一种维生素e胶囊及其制备方法 Download PDFInfo
- Publication number
- CN106265891A CN106265891A CN201610767936.6A CN201610767936A CN106265891A CN 106265891 A CN106265891 A CN 106265891A CN 201610767936 A CN201610767936 A CN 201610767936A CN 106265891 A CN106265891 A CN 106265891A
- Authority
- CN
- China
- Prior art keywords
- vitamin
- capsule
- content
- walnut oil
- glue
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 title claims abstract description 102
- 229930003427 Vitamin E Natural products 0.000 title claims abstract description 50
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 title claims abstract description 50
- 235000019165 vitamin E Nutrition 0.000 title claims abstract description 50
- 239000011709 vitamin E Substances 0.000 title claims abstract description 50
- 229940046009 vitamin E Drugs 0.000 title claims abstract description 50
- 239000002775 capsule Substances 0.000 title claims abstract description 48
- 238000002360 preparation method Methods 0.000 title abstract description 9
- 235000019498 Walnut oil Nutrition 0.000 claims abstract description 21
- 239000008170 walnut oil Substances 0.000 claims abstract description 21
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 claims abstract description 13
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 claims abstract description 13
- 239000002671 adjuvant Substances 0.000 claims abstract description 13
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 claims abstract description 13
- 235000012661 lycopene Nutrition 0.000 claims abstract description 13
- 239000001751 lycopene Substances 0.000 claims abstract description 13
- 229960004999 lycopene Drugs 0.000 claims abstract description 13
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 claims abstract description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 13
- 229920001661 Chitosan Polymers 0.000 claims abstract description 11
- 108010010803 Gelatin Proteins 0.000 claims abstract description 11
- 229920002774 Maltodextrin Polymers 0.000 claims abstract description 11
- 239000005913 Maltodextrin Substances 0.000 claims abstract description 11
- 229920000159 gelatin Polymers 0.000 claims abstract description 11
- 239000008273 gelatin Substances 0.000 claims abstract description 11
- 235000019322 gelatine Nutrition 0.000 claims abstract description 11
- 235000011852 gelatine desserts Nutrition 0.000 claims abstract description 11
- 229940035034 maltodextrin Drugs 0.000 claims abstract description 11
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims abstract description 9
- 229920000053 polysorbate 80 Polymers 0.000 claims abstract description 9
- 238000003756 stirring Methods 0.000 claims description 17
- 239000003292 glue Substances 0.000 claims description 16
- 230000001804 emulsifying effect Effects 0.000 claims description 10
- 238000001694 spray drying Methods 0.000 claims description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 9
- -1 selenocarrageenan Chemical compound 0.000 claims description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 5
- 230000009514 concussion Effects 0.000 claims description 4
- 239000000395 magnesium oxide Substances 0.000 claims description 3
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 claims description 3
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 claims description 3
- GRLPQNLYRHEGIJ-UHFFFAOYSA-J potassium aluminium sulfate Chemical group [Al+3].[K+].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O GRLPQNLYRHEGIJ-UHFFFAOYSA-J 0.000 claims description 3
- 241000195474 Sargassum Species 0.000 claims description 2
- 238000000034 method Methods 0.000 claims 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims 1
- 235000007688 Lycopersicon esculentum Nutrition 0.000 claims 1
- 240000003768 Solanum lycopersicum Species 0.000 claims 1
- SEGLCEQVOFDUPX-UHFFFAOYSA-N di-(2-ethylhexyl)phosphoric acid Chemical compound CCCCC(CC)COP(O)(=O)OCC(CC)CCCC SEGLCEQVOFDUPX-UHFFFAOYSA-N 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 1
- 230000003026 anti-oxygenic effect Effects 0.000 abstract description 4
- 235000016709 nutrition Nutrition 0.000 abstract description 2
- 230000035764 nutrition Effects 0.000 abstract description 2
- 230000000694 effects Effects 0.000 description 8
- 238000001035 drying Methods 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 210000000582 semen Anatomy 0.000 description 4
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 3
- 229960003180 glutathione Drugs 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 2
- 241000251774 Squalus Species 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- LFVGISIMTYGQHF-UHFFFAOYSA-N ammonium dihydrogen phosphate Chemical compound [NH4+].OP(O)([O-])=O LFVGISIMTYGQHF-UHFFFAOYSA-N 0.000 description 2
- 229910000387 ammonium dihydrogen phosphate Inorganic materials 0.000 description 2
- 230000003064 anti-oxidating effect Effects 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 230000003796 beauty Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 235000003969 glutathione Nutrition 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 235000019837 monoammonium phosphate Nutrition 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 229910052711 selenium Inorganic materials 0.000 description 2
- 239000011669 selenium Substances 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 229930003799 tocopherol Natural products 0.000 description 2
- 229960001295 tocopherol Drugs 0.000 description 2
- 239000011732 tocopherol Substances 0.000 description 2
- 235000010384 tocopherol Nutrition 0.000 description 2
- 230000037303 wrinkles Effects 0.000 description 2
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- 206010000234 Abortion spontaneous Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 208000009084 Cold Injury Diseases 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 229940123457 Free radical scavenger Drugs 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000002595 cold damage Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 235000004626 essential fatty acids Nutrition 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 208000015994 miscarriage Diseases 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 206010034754 petechiae Diseases 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 201000001514 prostate carcinoma Diseases 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000001054 red pigment Substances 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 230000037394 skin elasticity Effects 0.000 description 1
- 208000000995 spontaneous abortion Diseases 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 125000002640 tocopherol group Chemical group 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 208000012991 uterine carcinoma Diseases 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/52—Juglandaceae (Walnut family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明公开一种维生素E胶囊及其制备方法，包括胶囊内容物和胶囊皮，以维生素E胶囊总重计，所述胶囊内容物包括80‑90％的维生素E、0.01‑0.1％的硒化卡拉胶、0.05‑0.2％的番茄红素、3‑5％的核桃油、0.01‑0.05％的吐温‑80、余量为辅料；所述胶囊皮包括麦芽糊精30‑40％、明胶10‑15％、壳聚糖1‑5％、余量为水。本发明维生素E胶囊在维生素E为主要成分，适量加入硒化卡拉胶、高抗氧化性能的番茄红素、核桃油，具有协同作用，增加了维生素E的抗氧化性能，提供了丰富的营养，满足了人们对健康多元化的需要。
Description
技术领域
本发明涉及一种维生素E胶囊及其制备方法。
背景技术
维生素E(Vitamin E)是一种脂溶性维生素，其水解产物为生育酚，是最主要的抗氧化剂之一。多溶于脂肪和乙醇等有机溶剂中，不溶于水，对热、酸稳定，对碱不稳定，对氧敏感，对热不敏感，但油炸时维生素E活性明显降低。生育酚能促进性激素分泌，使男子精子活力和数量增加；使女子雌性激素浓度增高，提高生育能力，预防流产，还可用于防治男性不育症、烧伤、冻伤、毛细血管出血、更年期综合症、美容等方面。近来还发现维生素E可抑制眼睛晶状体内的过氧化脂反应，使末梢血管扩张，改善血液循环，预防近视眼发生和发展。我国推荐维生素E日摄入量为14mg，但由于维生素E不溶于水，一天摄取量的60-70％会随着排泄物排出体外，吸收时需要胆汁酸参与，肝病患者或患胆汁生成障碍的病人无法吸收利用。据有关文献报道，当乳液平均粒径500纳米时维生素E可被胃肠道直接吸收；乳液平均粒径100纳米时维生素E则可被口腔、鼻腔等粘膜直接吸收。因此研究水溶性维生素E，实现维生素E在模拟人体胃内条件下形成纳米级乳液(纳米级乳液是指液滴平均粒径≤100nm的乳液)，可同时解决上述吸收利用率低及肝病患者无法吸收的问题，具有极大的社会效益及经济效益。
硒是谷胱甘肽过氧化物酶(GSH-Px)的组成成分，每摩尔的GSH-Px中含4克原子硒，此酶的作用是催化还原性谷胱甘肽(GSH)与过氧化物的氧化还原反应，所以可发挥抗氧化作用，是重要的自由基清除剂(是维生素E的50-500倍)。在体内，GSH-Px与维生素E抗氧化的机制不同，两者可以互相补充，具有协同作用。
番茄红素(Lycopene)是类胡萝卜素的一种，是一种很强的抗氧化剂，具有极强的清除自由基的能力，对防治前列腺癌、肺癌、乳腺癌、子宫癌等有显著效果，有效抑制癌细胞的扩散和复制，还有预防心脑血管疾病、提高免疫力、保护细胞DNA免受自由基损害，防止细胞病变、突变、癌变；含强力抗氧化生物活物质，能促使细胞的生长和再生，美容袪皱，维持皮肤健康，延缓衰老等功效。
核桃油是采用核桃仁为原料，压榨而成的植物油，属于可食用油。核桃油有强身健体的作用：这是由于核桃能够提供充足的热量。每100克的核桃仁便可提供约630千卡的热量，相当于米饭热量的3-4倍。因此在冬天常吃些核桃还可以起到御寒的作用。核桃油有滋润皮肤的作用：核桃油富含与皮肤亲和力极佳的角鲨和人体必须脂肪酸。吸收迅速，有效保持皮肤弹性和润泽。核桃油有美容养颜的作用：这是由于核桃油富含人体必需脂肪酸，同时还富含一种与皮肤亲和力很强的角鲨稀。这两种物质能迅速被子皮肤所吸收，能有效保护皮肤的弹性的润泽；能消除面部皱纹，防止肌肤衰老；核桃油中不含胆固醇，可有效预防老年痴呆症的发生；丰富的亚油酸和亚麻酸能排除血管内新陈代谢的杂质，使血液净化，为大脑提供新鲜血液；能防止动脉硬化及动脉硬化并发症、高血压、心脏病、心力衰竭、肾衰竭、脑出血发生；这是因为核桃油中的dha可以增加胰岛素的敏感性，当细胞中不饱和脂肪酸含量越高，拥有的双健数量越多，其活动性就越强。
发明内容
本发明的目的在于提供一种维生素E胶囊及其制备方法。
本发明的目的可以通过以下技术方案实现：
一种维生素E胶囊，其特征在于，包括胶囊内容物和胶囊皮，以维生素E胶囊总重计，所述胶囊内容物包括80-90％的维生素E、0.01-0.1％的硒化卡拉胶、0.05-0.2％的番茄红素、3-5％的核桃油、0.01-0.05％的吐温-80、余量为辅料；所述胶囊皮包括麦芽糊精30-40％、明胶10-15％、壳聚糖1-5％、余量为水。
进一步方案，所述辅料为硫酸铝钾、磷酸二氢铵、钙质海藻、氧化镁、甘油、丙二醇中的至少一种。
一种维生素E胶囊的制备方法，包括以下步骤：
(1)制胶：按配比称取麦芽糊精、明胶、壳聚糖和水，加热到70-80℃，搅拌至完全溶解，冷却至室温，得胶液；
(2)制内容物：按配比称取核桃油、吐温-80、辅料混合，加热至30-35℃，搅拌30min，再依次加入维生素E、硒化卡拉胶、番茄红素，搅拌20min，冷却至室温，得内容物；
(3)乳化、喷雾干燥：将胶液和内容物以重量比1:6混合，置于25-30MPa振荡器上震荡24h，过均质机2次，配好的乳化混合剂在高速离心喷雾干燥器中进行干燥。
进一步方案，所述步骤(1)与步骤(2)搅拌速率为300r/min。
进一步方案，所述步骤(3)干燥温度为45-50℃，干燥时间为3-5h。
本发明的有益效果：本发明维生素E胶囊在维生素E为主要成分，适量加入硒化卡拉胶、高抗氧化性能的番茄红素、核桃油，具有协同作用，增加了维生素E的抗氧化性能，提供了丰富的营养，满足了人们对健康多元化的需要。
具体实施方式
下面结合具体实施例对本发明作进一步详细描述。
实施例1
一种维生素E胶囊，包括胶囊内容物和胶囊皮，以维生素E胶囊总重计，胶囊内容物包括80％的维生素E、0.05％的硒化卡拉胶、0.05％的番茄红素、5％的核桃油、0.01％的吐温-80、余量为辅料硫酸铝钾、磷酸二氢铵；胶囊皮包括麦芽糊精30％、明胶15％、壳聚糖1％、余量为水。
一种维生素E胶囊的制备方法，包括以下步骤：
(1)制胶：按配比称取麦芽糊精、明胶、壳聚糖和水，加热到70℃，300r/min搅拌至完全溶解，冷却至室温，得胶液；
(2)制内容物：按配比称取核桃油、吐温-80、辅料混合，加热至30℃，300r/min搅拌30min，再依次加入维生素E、硒化卡拉胶、番茄红素，搅拌20min，冷却至室温，得内容物；
(3)乳化、喷雾干燥：将胶液和内容物以重量比1:6混合，置于25MPa振荡器上震荡24h，过均质机2次，配好的乳化混合剂在高速离心喷雾干燥器中进行干燥，干燥温度为45℃，干燥时间为5h。
实施例2
一种维生素E胶囊，包括胶囊内容物和胶囊皮，以维生素E胶囊总重计，胶囊内容物包括90％的维生素E、0.01％的硒化卡拉胶、0.1％的番茄红素、3％的核桃油、0.05％的吐温-80、余量为辅料氧化镁；胶囊皮包括麦芽糊精35％、明胶10％、壳聚糖3％、余量为水。
一种维生素E胶囊的制备方法，包括以下步骤：
(1)制胶：按配比称取麦芽糊精、明胶、壳聚糖和水，加热到80℃，300r/min搅拌至完全溶解，冷却至室温，得胶液；
(2)制内容物：按配比称取核桃油、吐温-80、辅料混合，加热至35℃，300r/min搅拌30min，再依次加入维生素E、硒化卡拉胶、番茄红素，搅拌20min，冷却至室温，得内容物；
(3)乳化、喷雾干燥：将胶液和内容物以重量比1:6混合，置于30MPa振荡器上震荡24h，过均质机2次，配好的乳化混合剂在高速离心喷雾干燥器中进行干燥，干燥温度为48℃，干燥时间为4h。
实施例3
一种维生素E胶囊，包括胶囊内容物和胶囊皮，以维生素E胶囊总重计，胶囊内容物包括85％的维生素E、0.1％的硒化卡拉胶、0.2％的番茄红素、4％的核桃油、0.03％的吐温-80、余量为辅料甘油；胶囊皮包括麦芽糊精40％、明胶12％、壳聚糖5％、余量为水。
一种维生素E胶囊的制备方法，包括以下步骤：
(1)制胶：按配比称取麦芽糊精、明胶、壳聚糖和水，加热到75℃，300r/min搅拌至完全溶解，冷却至室温，得胶液；
(2)制内容物：按配比称取核桃油、吐温-80、辅料混合，加热至33℃，300r/min搅拌30min，再依次加入维生素E、硒化卡拉胶、番茄红素，搅拌20min，冷却至室温，得内容物；
(3)乳化、喷雾干燥：将胶液和内容物以重量比1:6混合，置于25MPa振荡器上震荡24h，过均质机2次，配好的乳化混合剂在高速离心喷雾干燥器中进行干燥，干燥温度为50℃，干燥时间为3h。
上述的对实施例的描述是为便于该技术领域的普通技术人员能理解和应用本发明。熟悉本领域技术的人员显然可以容易地对实施案例做出各种修改，并把在此说明的一般原理应用到其他实施例中而不必经过创造性的劳动。因此，本发明不限于这里的实施案例，本领域技术人员根据本发明的揭示，不脱离本发明范畴所做出的改进和修改都应该在本发明的保护范围之内。
Claims (5)
1.一种维生素E胶囊，其特征在于，包括胶囊内容物和胶囊皮，以维生素E胶囊总重计，所述胶囊内容物包括80-90％的维生素E、0.01-0.1％的硒化卡拉胶、0.05-0.2％的番茄红素、3-5％的核桃油、0.01-0.05％的吐温-80、余量为辅料；所述胶囊皮包括麦芽糊精30-40％、明胶10-15％、壳聚糖1-5％、余量为水。
2.根据权利要求1所述的一种维生素E胶囊，其特征在于，所述辅料为硫酸铝钾、磷酸二氢铵、钙质海藻、氧化镁、甘油、丙二醇中的至少一种。
3.一种制备如权利要求1所述的维生素E胶囊的方法，其特征在于，包括以下步骤：
(1)制胶：按配比称取麦芽糊精、明胶、壳聚糖和水，加热到70-80℃，搅拌至完全溶解，冷却至室温，得胶液；
(2)制内容物：按配比称取核桃油、吐温-80、辅料混合，加热至30-35℃，搅拌30min，再依次加入维生素E、硒化卡拉胶、番茄红素，搅拌20min，冷却至室温，得内容物；
(3)乳化、喷雾干燥：将胶液和内容物以重量比1:6混合，置于25-30MPa振荡器上震荡24h，过均质机2次，配好的乳化混合剂在高速离心喷雾干燥器中进行干燥。
4.根据权利要求3所述的方法，其特征在于，所述步骤(1)与步骤(2)搅拌速率为300r/min。
5.根据权利要求3所述的方法，其特征在于，所述步骤(3)干燥温度为45-50℃，干燥时间为3-5h。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610767936.6A CN106265891A (zh) | 2016-08-30 | 2016-08-30 | 一种维生素e胶囊及其制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610767936.6A CN106265891A (zh) | 2016-08-30 | 2016-08-30 | 一种维生素e胶囊及其制备方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106265891A true CN106265891A (zh) | 2017-01-04 |
Family
ID=57675695
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610767936.6A Pending CN106265891A (zh) | 2016-08-30 | 2016-08-30 | 一种维生素e胶囊及其制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106265891A (zh) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109222104A (zh) * | 2018-09-03 | 2019-01-18 | 哈尔滨快好药业有限公司 | 一种用于补充维生素e及多种矿物质的保健食品及其制备方法和应用 |
| CN112220046A (zh) * | 2020-10-28 | 2021-01-15 | 青岛鹏洋生物工程有限公司 | 一种含硒化卡拉胶的复配营养强化剂及其制备方法 |
| CN114145452A (zh) * | 2021-12-10 | 2022-03-08 | 青岛圣桐营养食品有限公司 | 特殊医学用途全营养配方食品 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102772389A (zh) * | 2012-08-22 | 2012-11-14 | 广东仙乐制药有限公司 | 一种水溶性维生素e软胶囊及其制备方法 |
| CN102824371A (zh) * | 2012-08-23 | 2012-12-19 | 石药集团中奇制药技术（石家庄）有限公司 | 一种蜂胶番茄红素组合物及其制备方法 |
| CN105853458A (zh) * | 2016-04-25 | 2016-08-17 | 湖南中硒生物科技有限公司 | 一种维生素e硒及其制备方法 |
-
2016
- 2016-08-30 CN CN201610767936.6A patent/CN106265891A/zh active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102772389A (zh) * | 2012-08-22 | 2012-11-14 | 广东仙乐制药有限公司 | 一种水溶性维生素e软胶囊及其制备方法 |
| CN102824371A (zh) * | 2012-08-23 | 2012-12-19 | 石药集团中奇制药技术（石家庄）有限公司 | 一种蜂胶番茄红素组合物及其制备方法 |
| CN105853458A (zh) * | 2016-04-25 | 2016-08-17 | 湖南中硒生物科技有限公司 | 一种维生素e硒及其制备方法 |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109222104A (zh) * | 2018-09-03 | 2019-01-18 | 哈尔滨快好药业有限公司 | 一种用于补充维生素e及多种矿物质的保健食品及其制备方法和应用 |
| CN112220046A (zh) * | 2020-10-28 | 2021-01-15 | 青岛鹏洋生物工程有限公司 | 一种含硒化卡拉胶的复配营养强化剂及其制备方法 |
| CN114145452A (zh) * | 2021-12-10 | 2022-03-08 | 青岛圣桐营养食品有限公司 | 特殊医学用途全营养配方食品 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106265891A (zh) | 一种维生素e胶囊及其制备方法 | |
| CN105613789A (zh) | 一种高脂高膳食纤维复合动植物粉末油脂、其制备方法及应用 | |
| CN106165905B (zh) | 一种钙加维生素软胶囊及制备方法 | |
| CN106035752A (zh) | 一种富含植物甾醇的多不饱和油脂粉末及其制备方法 | |
| WO2020207505A2 (zh) | 一种中碳链脂肪酸粉末油脂及其制备方法 | |
| CN106867856A (zh) | 一种亚麻籽油保健醋及其制备方法 | |
| CN102885245A (zh) | 一种含有番茄红素的复合微囊粉及其制备方法 | |
| CN105456225B (zh) | 一种维生素e软胶囊及其制备方法 | |
| CN101401779A (zh) | 含有复合植物多酚提取物的化妆品组合物及其制备方法 | |
| CN102078365A (zh) | 一种具有辅助降血脂功能的软胶囊及其制备方法 | |
| CN110326789A (zh) | 一种脂肪乳食品补充液及其制备方法 | |
| CN102885860A (zh) | 一种增强免疫力的灵芝孢子油软胶囊及其制备方法 | |
| CN101999649B (zh) | 一种抗氧化保健品组合物及其制备方法 | |
| CN110115386A (zh) | 一种改善卵巢功能的营养组合物及其制备方法 | |
| CN108295116A (zh) | 一种富硒保健组合物、胶囊及其制备方法 | |
| CN106937746A (zh) | 硒加钙软胶囊及制备方法 | |
| CN103393590B (zh) | 一种纳米灵芝孢子油的生产工艺 | |
| CN107006622A (zh) | 一种养生食用油及其制备方法 | |
| CN103860430B (zh) | 一种美容面膜及其制备方法 | |
| CN108851058A (zh) | 一种富含α-亚麻酸的多种维生素矿物质软胶囊及其制备方法 | |
| CN110050847A (zh) | 一种生酮饮食和脂肪酸混合食用植物调和油 | |
| CN113115954A (zh) | 一种钙维生素d3维生素k2保健食品及其制备方法 | |
| CN1861061A (zh) | 治疗或预防新生儿出血症的药物 | |
| CN109198643A (zh) | 一种裂壶藻dha油脂谷物代餐冲调粉及其制备方法 | |
| CN106509890A (zh) | 一种缓解女性更年期综合症的组合物及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20170104 |
|
| WD01 | Invention patent application deemed withdrawn after publication |